This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Immunization  • Neurology  • Cardiovascular System, Other  • Pediatrics  • Adolescent Medicine  • Adverse Effects  • Alert me on articles by topic

JAMA. 2008;299(21):2502-2506.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2008;57:457-460

1 figure, 1 table omitted

Syncope (vasovagal reaction), or fainting, can be triggered by various stimuli, including medical procedures.^1-3 Syncope has been documented to occur after vaccination, most commonly among adolescents, and can result in hospitalization for a medical evaluation or because of injury.^{2, 4} During 2005 and 2006, the Advisory Committee on Immunization Practices (ACIP) recommended use of three newly licensed vaccines for adolescents*: the quadrivalent human papillomavirus recombinant vaccine (HPV) (Gardasil®, Merck & Co., Inc., Whitehouse Station, New Jersey) in a 3-dose series, the quadrivalent meningococcal conjugate vaccine (MCV4) (Menactra®, Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) in a single dose, and the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) (Adacel®, Sanofi Pasteur; Boostrix®, GlaxoSmithKline Biologicals, Research Triangle Park, North Carolina) in a single dose. To describe trends in occurrence of postvaccination syncope, CDC and the Food and Drug Administration (FDA) analyzed data from the Vaccine . . . [Full Text of this Article]

Case 1